Showing results (391-400 of 2,410) with videos related to
Sort By:
Pageof 241
Journal of Medical Economics|March 8, 2019
The importance of accounting for the uncertainty around the preference-based health-related quality-of-life measures value sets: a systematic reviewSamer A Kharroubi, Yara BeyhJournal of Medical Economics|August 22, 2019
The association of pain interference and opioid use with healthcare utilization and costs, and wage loss among adults with osteoarthritis in the United StatesXiaohui Zhao, Drishti Shah, Kavita Gandhi, et al.Journal of Medical Economics|August 22, 2019
Cost-effectiveness of rivaroxaban versus apixaban for the initial treatment of venous thromboembolism and extended prevention of recurrences in the UKKerstin Folkerts, Julie Broughton, Usman Sheikh, et al.Journal of Medical Economics|August 22, 2019
Febrile neutropenia hospitalization due to pegfilgrastim on-body injector failure compared to single-injection pegfilgrastim and daily injections with reference and biosimilar filgrastim: US cost simulation for lung cancer and non-Hodgkin lymphomaAli McBride, Andriy Krendyukov, Nicola Mathieson, et al.Journal of Medical Economics|April 4, 2019
Healthcare costs of stroke and major bleeding in patients with atrial fibrillation treated with non-vitamin K antagonist oral anticoagulantsHeather M Rozjabek, Craig I Coleman, Veronica Ashton, et al.Journal of Medical Economics|August 28, 2019
Cost-effectiveness model of abiraterone plus prednisone, cabazitaxel plus prednisone and enzalutamide for visceral metastatic castration resistant prostate cancer therapy after docetaxel therapy resistanceYazan K Barqawi, Matthew E Borrego, Melissa H Roberts, et al.Journal of Medical Economics|October 24, 2018
Does an economic incentive affect provider behavior? Evidence from a field experiment on different payment mechanismsXiaoyu Xi, Ennan Wang, Qianni Lu, et al.Journal of Medical Economics|October 23, 2018
Cost-effectiveness analysis of secukinumab in ankylosing spondylitis from the Canadian perspectiveRon Goeree, Sima Chiva-Razavi, Praveen Gunda, et al.Journal of Medical Economics|November 14, 2018
A review and validation of overall survival extrapolation in health technology assessments of cancer immunotherapy by the National Institute for Health and Care Excellence: how did the initial best estimate compare to trial data subsequently made available?Ash Bullement, Yang Meng, Miranda Cooper, et al.Journal of Medical Economics|August 27, 2020
Economic burden and risk factors of migraine disease progression in the US: a retrospective analysis of a commercial payer databaseShonda A Foster, Chi-Chang Chen, Yao Ding, et al.Pageof 241